Email updates

Keep up to date with the latest news and content from Radiation Oncology and BioMed Central.

Open Access Research

MVP expression in the prediction of clinical outcome of locally advanced oral squamous cell carcinoma patients treated with radiotherapy

Luis Alberto Henríquez-Hernández123*, Mercedes Moreno4, Agustín Rey5, Marta Lloret123 and Pedro C Lara123

Author Affiliations

1 Radiation Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Barranco de La Ballena s/n., Las Palmas de Gran Canaria, CP 35010, Spain

2 Instituto Canario de Investigación del Cáncer (ICIC), Las Palmas de Gran Canaria, Spain

3 Clinical Sciences Department, Universidad de Las Palmas de Gran Canaria

4 Department of Maxillofacial Surgery, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain

5 Department of Pathology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain

For all author emails, please log on.

Radiation Oncology 2012, 7:147  doi:10.1186/1748-717X-7-147

Published: 29 August 2012



To explore the role of Major Vault Protein (MVP) in oral cavity squamous cell carcinoma patients.

Subjects and Methods

131 consecutive patients suffering from oral cavity squamous cell carcinoma were included in the study. In the whole series, the mean follow-up for survivors was 123.11 ± 40.36 months. Patients in tumour stages I and II were referred to surgery; patients in stage III-IV to postoperative radiotherapy (mean dose = 62.13 ± 7.74 Gy in 1.8–2 Gy/fraction). MVP expression was studied by immunohistochemistry in paraffin-embedded tumour tissue.


MVP expression was positive in 112 patients (85.5%) and no relation was found with clinic pathological variables. MVP overexpression (those tumours with moderate or strong expression of the protein) was related to insulin-like growth factor receptor-1 (IGF-1R) expression (P = 0.014). Tumour stage of the disease was the most important prognostic factor related to survival. Tumours overexpressing MVP and IGF-1R were strongly related to poor disease-free survival (P = 0.008, Exp(B) = 2.730, CI95% (1.302-5.724)) and cause-specific survival (P = 0.014, Exp(B) = 2.570, CI95% (1.215-5.437)) in patients achieving tumour stages III-IV, in multivariate analysis.


MVP and IGF-1R expression were related in oral squamous cell carcinoma and conferred reduced long-term survival in patients suffering from advanced stages of the disease.

MVP; IGF-1R; Oral carcinoma; Radiotherapy; Predictive factor